| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Tau protein
|
|---|---|
| ln Vitro |
The peptide promotes the aggregation of tau protein into paired helical filaments (PHFs), which are the primary components of neurofibrillary tangles (NFTs) found in Alzheimer's disease. It is used to study the biochemical and structural basis of tau aggregation and to screen for tau aggregation inhibitors.
|
| ln Vivo |
The in vivo activity of this peptide is linked to the formation of tau aggregates, which are neurotoxic. In animal models, direct injection of the peptide into the brain may induce tauopathy-like pathology. It serves as a tool for modeling tau aggregation for therapeutic studies.
|
| Enzyme Assay |
In a standard in vitro assay, the peptide is first dissolved in a solvent like DMSO to make a stock solution. For aggregation studies, the peptide is then diluted into a fibrillation buffer (e.g., 10 mM HEPES, 50 mM NaCl, pH 7.4) at a concentration of around 100 uM. The sample is incubated at 37degC with constant shaking. Aggregate formation is monitored over time using thioflavin T fluorescence.
|
| Cell Assay |
For cell-based experiments, tau-overexpressing HEK293 or SH-SY5Y cells are seeded in culture plates. The cells are then treated with various concentrations of the Acetyl-PHF6 amide peptide, which is taken up by the cells. After an incubation period (e.g., 24-48 hours), the cells are fixed and stained with tau-specific antibodies. The formation of tau aggregates is quantified by immunofluorescence microscopy or a cell-based FRET assay.
|
| Animal Protocol |
In an animal model, the peptide is typically aggregated in vitro to form pre-formed fibrils (PFFs). Under anesthesia, mice or rats are placed in a stereotaxic frame. A small volume (e.g., 2 uL) of the PFF solution is injected into a specific brain region, such as the hippocampus or the entorhinal cortex. The animals are allowed to recover and aged for several weeks. Brain sections are later stained to assess the spread of tau pathology.
|
| ADME/Pharmacokinetics |
As a peptide, Ac-PHF6 is expected to have a short half-life in vivo due to rapid proteolytic degradation. Its ability to cross the blood-brain barrier is very limited. When injected directly into the brain, it has a longer local half-life, particularly in its aggregated form. PK studies are not typically performed for such a research tool.
|
| Toxicity/Toxicokinetics |
No formal toxicology studies have been published for this research peptide. Potential toxicity is linked to the induction of tau aggregation and subsequent neurotoxicity. Based on its mechanism, relevant toxicities would be neurological, such as memory loss and motor deficits. This product is strictly for research use.
|
| References | |
| Additional Infomation |
The PHF6 (VQIVYK) motif is the primary hexapeptide responsible for initiating tau aggregation. Studying this peptide helps in understanding the core mechanism of tauopathies. It is used to develop and test potential disease-modifying therapeutics, like aggregation inhibitors. This product is not for human therapeutic use.
|
| Molecular Formula |
C40H64F3N9O11
|
|---|---|
| Molecular Weight |
903.99
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~67.5 mg/mL (~74.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.25 mg/mL (2.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1062 mL | 5.5310 mL | 11.0621 mL | |
| 5 mM | 0.2212 mL | 1.1062 mL | 2.2124 mL | |
| 10 mM | 0.1106 mL | 0.5531 mL | 1.1062 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
